DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N. et al.
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol 2016;
17: 78-89
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.